UNIVERSITY OF CALIFORNIA, DAVIS
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 1905-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.ucdavis.edu
Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer
- First Posted Date
- 2006-12-07
- Last Posted Date
- 2017-06-09
- Lead Sponsor
- University of California, Davis
- Registration Number
- NCT00408772
- Locations
- 🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States
Lapatinib and Vinorelbine in Treating Patients With Advanced Solid Tumors
- Conditions
- Interventions
- Drug: lapatinib ditosylateDrug: Vinorelbine ditartrateGenetic: comparative genomic hybridizationGenetic: cytogenetic analysisGenetic: gene expression analysisGenetic: mutation analysisGenetic: polymerase chain reactionGenetic: polymorphism analysisGenetic: proteomic profilingGenetic: reverse transcriptase-polymerase chain reactionOther: immunohistochemistry staining methodOther: laboratory biomarker analysis
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2012-04-19
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 22
- Registration Number
- NCT00389922
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸University of California Davis Cancer Center, Sacramento, California, United States
Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
- Conditions
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 27
- Registration Number
- NCT00389805
- Locations
- 🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States
Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2018-12-06
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 81
- Registration Number
- NCT00390429
- Locations
- 🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States
Irinotecan and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Solid Tumors
- Conditions
- Unspecified Adult Solid Tumor, Protocol SpecificUnspecified Childhood Solid Tumor, Protocol SpecificLong-term Effects Secondary to Cancer Therapy in ChildrenPoor Performance StatusBrain and Central Nervous System TumorsCognitive/Functional EffectsLong-term Effects Secondary to Cancer Therapy in Adults
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 30
- Registration Number
- NCT00389584
- Locations
- 🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States
Bortezomib and Topotecan in Treating Patients With Advanced Solid Tumors
- Conditions
- First Posted Date
- 2006-10-13
- Last Posted Date
- 2010-06-29
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 24
- Registration Number
- NCT00388089
- Locations
- 🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States
Irinotecan and Carboplatin in Treating Patients With Metastatic or Recurrent Small Cell Lung Cancer
- First Posted Date
- 2006-10-13
- Last Posted Date
- 2018-01-10
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 80
- Registration Number
- NCT00387660
- Locations
- 🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States
Radiofrequency Ablation in Treating Patients With Early Invasive Breast Cancer or Ductal Carcinoma in Situ
- Conditions
- Interventions
- First Posted Date
- 2006-10-13
- Last Posted Date
- 2010-03-29
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 15
- Registration Number
- NCT00388115
- Locations
- 🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States
Pemetrexed Disodium and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2006-10-13
- Last Posted Date
- 2010-03-29
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 42
- Registration Number
- NCT00387322
- Locations
- 🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States
Effects of L-Carnitine on Postprandial Clearance of Triglyceride-rich Lipoproteins in HIV Patients on HAART
- Conditions
- Interventions
- First Posted Date
- 2006-10-12
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 13
- Registration Number
- NCT00386971
- Locations
- 🇺🇸
GCRC UC Davis, Sacramento, California, United States